Khi được bạn cho phép, chúng tôi sử dụng phân tích giới hạn, chú trọng quyền riêng tư để hiểu hành trình nghiên cứu nào hiệu quả. Chúng tôi không dùng trình theo dõi quảng cáo hoặc ghi lại phiên. Bạn có thể thay đổi lựa chọn này trong Tùy chọn. Đọc Chính sách quyền riêng tư.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
UNH — frequently asked questions
Is UnitedHealth Group Incorporated overvalued?
In our latest published analysis dated 2026-09-21, UNH looks meaningfully undervalued. The price recorded at analysis is 377 USD versus our fair value of 448 USD; the high endpoint is presented separately as potential value of 578 USD. That implies roughly 18.9% upside to fair value at that date.
Our latest published report, analyzed 2026-09-21, gives UNH a fair value of 448 USD and a potential value of 578 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for UnitedHealth Group Incorporated's archetype; it is a dated research output, not a live price.
Should I buy UNH now?
Our latest published rating for UNH, analyzed 2026-09-21, is Buy. UnitedHealth Group Incorporated looks meaningfully undervalued at the analysis-date price of 377 USD versus fair value of 448 USD; potential value is 578 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for UNH?
The dedicated bear-case section in our report analyzed 2026-09-21 documents UnitedHealth Group Incorporated's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is UNH's rating?
Our latest published rating for UNH, analyzed 2026-09-21, is Buy, with a published moat assessment of 7/10 (Narrow). It reflects our fair value of 448 USD, the potential value of 578 USD, and the price recorded at analysis (377 USD).
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.
§1 Tóm tắt điều hànhEN
Câu trả lời trong 30 giâyBuy
Giá so với giá trị
Giá
$376.90
Giá trị hợp lý
$448.25
Giá trị tiềm năng
$578.10
Tính đến
2026-09-18
Vì sao luận điểm có thể đúng
Accelerating clinical margin recovery in OptumHealth combined with commercial health benefit premium repricing that absorbs medical cost inflation, driving operating margins from 4.24% in FY2025 toward historical levels of 6.50% and expanding fair value toward Potential value of USD 578.10.
We rate UnitedHealth Group a Buy. The company's massive scale in health benefits and integrated pharmacy services positions it for steady cash generation and earnings recovery, offering attractive upside from the report-date price to our Fair value.
Our rating is Buy. For an investor, this means UnitedHealth Group offers an attractive balance of steady compounding and share price appreciation, supported by leading positions in health benefits and healthcare services.
The report was prepared at a price of USD 376.90 on September 18, 2026. This price trades at a 15.92% discount to our Fair value of USD 448.25. If clinical care margins recover faster than expected, the shares could reach Potential value of USD 578.10.4
The main risk that would change our view is regulatory rate pressure from Medicare and Medicaid, which account for 44.0% of consolidated revenue. If federal payment benchmarks are cut or risk-adjustment coding audits tighten, premium yields per member would decline while medical utilization remains elevated. A reader would see this happen through consolidated operating margins dropping below 3.50% and annual free cash flow falling below $12,000M.7
The primary reason the investment can work is UnitedHealth's vertically integrated scale across health benefits and pharmacy care. UnitedHealthcare delivered $344.9B in revenue and OptumRx produced $7.19B in operating profit. By combining health insurance with prescription management, the business manages care costs more effectively than pure-play peers. As medical care ratios stabilize and clinic profitability recovers from recent deficits, operating profit and free cash flow will expand, driving per-share value toward our Fair value of USD 448.25.7
Unmatched Scale in Benefits and Pharmacy Care
UnitedHealthcare's $344.9B revenue base and OptumRx's $7.19B operating profit create unmatched contracting scale and lower unit operating costs than managed care peers.7
Strong operating cash flow of $19.7B and free cash flow of $16.1B fund dependable dividends and share repurchases, driving compounding per-share value as operating margins normalize toward historical levels.5,6
Scale and Cost Advantage in Benefits and Care Delivery
UnitedHealthcare generated $344,903M in FY2025 revenue and $9,425M in operating earnings, providing unprecedented purchasing scale and lower administrative unit costs than regional managed care peers.7
Khuyến nghị của hãng
We recommend a Buy because UnitedHealth Group's integrated scale across health benefits and pharmacy services provides durable cash flow to drive share price recovery to our Fair value.
Tổng quan công ty
It also offers direct-to-consumer solutions. On January 1, 2026, the company realigned certain of its businesses to respond to changes in the markets the company serves and the opportunities that are emerging as the health system evolves.
Optum Financial, including Optum Bank, which was historically included in Optum Health, will now be included in Optum Insight.
§2 Kịch bản tiêu cựcEN
Under persistent CMS statutory reimbursement cuts on the 44.0% government revenue share combined with elevated medical utilization, operating income falls below FY2025 levels of $18,964M. Free cash flow contracts from $16,075M as debt service on $73,328M total debt limits capital return flexibility.
Medical utilization remains elevated, holding consolidated operating margins depressed
OptumHealth capitation contract deficits widen further
The Bear path envisions persistent CMS Medicare Advantage statutory rate cuts, aggressive risk adjustment coding audits, and elevated medical utilization compressing consolidated operating margins. This scenario would be confirmed if medical care ratios remain elevated and clinic operating losses deepen, leading to reduced earnings power.
Các cách luận điểm này có thể đổ vỡ
Severe Medicare Advantage Rate Cuts and Medical Loss Ratio Spike Compress Consolidated Operating Margin Below 3.5%
CMS accounts for 44.0% of consolidated revenue and consolidated operating profit dropped from $32,358M in FY2023 to $18,964M in FY2025 (a 4.24% margin). A further 100-150 bps contraction pushes operating margin below 3.5%.6,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Tín hiệu cảnh báo sớm cần theo dõi
Năm diễn biến có thể làm suy yếu luận điểm đầu tư của chúng tôi.
01
consolidated_operating_margin
Medical loss ratio spikes and CMS rate reset pressures reducing operating profit below $16.0B across $447.6B revenue.
Hiện tại:4.24% in FY2025
Cảnh báo nếubelow 3.50%
02
operating_optumhealth_operating_income_millions
§3 Lợi thế cạnh tranhEN
Narrow
UnitedHealth Group possesses a narrow economic moat grounded in the structural cost and scale advantages of its dual-platform model spanning UnitedHealthcare and Optum. The combination of health insurance coverage with integrated pharmacy care services and clinical care delivery creates substantial customer switching costs.
High regulatory exposure to government programs where CMS represents 44.0% of revenue caps potential economic rent extraction, bounding the moat rating at narrow despite superior returns over capital costs.
01Scale and Cost Advantage in Benefits and Care Delivery — UnitedHealthcare generated $344,903M in FY2025 revenue and $9,425M in operating earnings, providing unprecedented purchasing scale and lower administrative unit costs than regional managed care peers.Wide
02High Switching Costs via Integrated PBM and Clinical Services — OptumRx delivered $154,726M in revenue and $7,193M in operating income, while OptumInsight generated $19,417M in revenue, embedding software, data analytics, and pharmacy benefit workflows deep within employer and health system operations.
Mối đe dọa đã biết với lợi thế cạnh tranh
Mối đe dọa
Mức độ
Mốc thời gian
Giảm thiểu
CMS Regulatory Reset and Risk-Adjustment Audit Tightening
high
12-24 months
Broad commercial employer diversification generating over $250B in non-CMS revenues alongside value-based care clinical risk sharing through Optum.
Clinical Care Delivery Cost Escalation at OptumHealth
The highlighted cell is Fair value when every assumption sits at its base level ($448.25). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $16.0B after modeled reinvestment of $0, with terminal value at 63.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
In FY2025, UNH allocated capital across $7,916M in common dividends and $5,545M in share repurchases, reducing diluted share count from 938M in FY2023 to 911M in FY2025. Total debt of $73,328M is supported by steady cash generation.
ROIC stood at 9.66% in FY2025, while operating margin rebounded in the first half of 2026, where Q2-2026 YTD operating profit reached $16,981M (a 7.59% operating margin), recovering from the 4.24% operating margin recorded in FY2025.
ROIC of 9.66% comfortably exceeds the computed WACC of 7.43%, creating positive economic profit across the business.
UnitedHealthcare generated $344,903M of UNH's $447,567M consolidated revenue in FY2025.
Scale provides steady operational cash flow even during periods of elevated medical care ratios.
Doanh thu mới nhất447,6 T US$CAGR doanh thu +10,3%
Biên hoạt động4,2%10 kỳ tài chính
Dòng tiền tự do mới nhất16,1 T US$FY2025
Nợ ròng50,3 T US$FY2025
Phân tích báo cáo kết quả kinh doanhQuy mô kinh doanh chuyển thành lợi nhuận báo cáo như thế nào.
StockMarketAgent.AI
Doanh thu447,6 T US$Giá vốn doanh thu−364,7 T US$Lợi nhuận gộp82,9 T US$Chi phí hoạt động−64 T US$Lợi nhuận hoạt động19 T US$Các khoản ngoài hoạt động và thuế−6,9 T US$Lợi nhuận ròng12,1 T US$
Dữ liệu lịch sử tài chính
Doanh thu
447.567.000.000 US$
Giá vốn doanh thu
364.650.000.000 US$
Lợi nhuận gộp
82.917.000.000 US$
Chi phí hoạt động
63.953.000.000 US$
Lợi nhuận hoạt động
18.964.000.000 US$
Các khoản ngoài hoạt động và thuế
-6.908.000.000 US$
Lợi nhuận ròng
12.056.000.000 US$
Tổng quan bảng cân đối kế toánCách tài sản đã báo cáo được nắm giữ và tài trợ trong kỳ đã chọn.
StockMarketAgent.AI
Cơ cấu tài sảnNguồn tài trợ
Tổng tài sản309,6 T US$Tiền mặt24,4 T US$Tài sản ngắn hạn90,6 T US$Tổng nợ phải trả207,9 T US$Nợ ngắn hạn114,9 T US$Vốn chủ sở hữu100,1 T US$
Dữ liệu phân tích bảng cân đối kế toán
Tổng tài sản
309.581.000.000 US$
Tiền mặt
24.365.000.000 US$
Tài sản ngắn hạn
90.582.000.000 US$
Tổng nợ phải trả
207.883.000.000 US$
Nợ ngắn hạn
114.897.000.000 US$
Vốn chủ sở hữu
100.090.000.000 US$
Cầu nối dòng tiềnDòng tiền từ hoạt động chuyển thành dòng tiền tự do như thế nào trong FY2025.
StockMarketAgent.AI
Đối chiếu dòng tiền hoạt động
Lợi nhuận ròng12,1 T US$Khấu hao và phân bổ+4,4 T US$Thù lao bằng cổ phiếu+971 Tr US$Điều chỉnh hoạt động khác+2,3 T US$Dòng tiền hoạt động19,7 T US$
Đối chiếu tiền đầu kỳ đến cuối kỳ
Tiền đầu kỳ25,3 T US$Dòng tiền hoạt động+19,7 T US$Dòng tiền đầu tư−8,7 T US$Dòng tiền tài chính−11,6 T US$Ảnh hưởng tỷ giá+40 Tr US$Tiền cuối kỳ24,4 T US$
19,7 T US$ − 3,6 T US$Dòng tiền tự do 16,1 T US$
Dữ liệu cầu nối dòng tiền
Lợi nhuận ròng
12.056.000.000 US$
Dòng tiền vào từ hoạt động
19.697.000.000 US$
Khấu hao và phân bổ
4.361.000.000 US$
Thù lao bằng cổ phiếu
971.000.000 US$
Điều chỉnh hoạt động khác
2.309.000.000 US$
Dòng tiền hoạt động
19.697.000.000 US$
Tiền sẵn có
45.049.000.000 US$
Tiền đầu kỳ
25.312.000.000 US$
Ảnh hưởng tỷ giá
40.000.000 US$
Dòng tiền ra từ đầu tư
8.685.000.000 US$
Capex
3.622.000.000 US$
Hoạt động đầu tư khác
5.063.000.000 US$
Dòng tiền ra từ tài chính
11.644.000.000 US$
Tiền cuối kỳ
24.365.000.000 US$
Dòng tiền đầu tư
-8.685.000.000 US$
Dòng tiền tài chính
-11.644.000.000 US$
Doanh thu và lợi nhuậnQuy mô kinh doanh chuyển thành lợi nhuận báo cáo như thế nào.
Tiền mặt và nợThanh khoản sẵn có so với tổng dư nợ.
Tạo dòng tiềnDòng tiền hoạt động so với dòng tiền tự do.
Khả năng sinh lờiDiễn biến biên gộp, biên hoạt động và biên ròng.
Dữ liệu tài chính tại thời điểm được dùng trong phân tích ngày 2026-09-21.
Dữ liệu lịch sử tài chính
Kỳ
Doanh thu
EBITDA
Lợi nhuận ròng
Dòng tiền hoạt động
Dòng tiền tự do
Capex
Khấu hao và phân bổ
Thù lao bằng cổ phiếu
Mua lại cổ phiếu
Cổ tức đã trả
Phát hành nợ ròng
Dòng tiền đầu tư
Dòng tiền tài chính
Tiền đầu kỳ
Tiền cuối kỳ
Tiền mặt và đầu tư
Tổng nợ
Biên hoạt động
ROIC
WACC
Chênh lệch ROIC−WACC
2016-12-31
184,8 T US$
15 T US$
7 T US$
9,8 T US$
8,1 T US$
1,7 T US$
2,1 T US$
485 Tr US$
1,3 T US$
2,3 T US$
—
-9,4 T US$
-1 T US$
—
10,4 T US$
13,3 T US$
33 T US$
7,0%
—
4,9%
—
2017-12-31
201,2 T US$
17,5 T US$
10,6 T US$
13,6 T US$
11,6 T US$
2 T US$
2,2 T US$
597 Tr US$
1,5 T US$
2,8 T US$
—
-8,6 T US$
-3,4 T US$
10,4 T US$
12 T US$
15,5 T US$
31,7 T US$
7,6%
—
5,2%
—
2018-12-31
226,2 T US$
19,8 T US$
12 T US$
15,7 T US$
13,7 T US$
2,1 T US$
2,4 T US$
638 Tr US$
4,5 T US$
3,3 T US$
—
-12,4 T US$
-4,4 T US$
12 T US$
10,9 T US$
14,3 T US$
36,6 T US$
7,7%
—
5,8%
—
2019-12-31
242,2 T US$
22,4 T US$
13,8 T US$
18,5 T US$
16,4 T US$
2,1 T US$
2,7 T US$
697 Tr US$
5,5 T US$
3,9 T US$
—
-12,7 T US$
-5,6 T US$
10,9 T US$
11 T US$
14,2 T US$
40,7 T US$
8,1%
—
4,9%
—
2020-12-31
257,1 T US$
25,3 T US$
15,4 T US$
22,2 T US$
20,1 T US$
2,1 T US$
2,9 T US$
679 Tr US$
4,3 T US$
4,6 T US$
—
-12,5 T US$
-3,6 T US$
11 T US$
16,9 T US$
19,8 T US$
43,5 T US$
8,7%
—
4,0%
—
2021-12-31
287,6 T US$
27,1 T US$
17,3 T US$
22,3 T US$
19,9 T US$
2,5 T US$
3,1 T US$
800 Tr US$
5 T US$
5,3 T US$
—
-10,4 T US$
-7,5 T US$
16,9 T US$
21,4 T US$
23,9 T US$
46 T US$
8,3%
—
4,8%
—
2022-12-31
324,2 T US$
31,8 T US$
20,1 T US$
26,2 T US$
23,4 T US$
2,8 T US$
3,4 T US$
925 Tr US$
7 T US$
6 T US$
12,5 T US$
-28,5 T US$
4,2 T US$
21,4 T US$
23,4 T US$
27,9 T US$
57,6 T US$
8,8%
—
6,9%
—
2023-12-31
371,6 T US$
36,3 T US$
22,4 T US$
29,1 T US$
25,7 T US$
3,4 T US$
4 T US$
1,1 T US$
8 T US$
6,8 T US$
4,3 T US$
-15,6 T US$
-11,5 T US$
23,4 T US$
25,4 T US$
29,6 T US$
67,4 T US$
8,7%
—
6,5%
—
2024-12-31
400,3 T US$
28,1 T US$
14,4 T US$
24,2 T US$
20,7 T US$
3,5 T US$
4,1 T US$
1 T US$
9 T US$
7,5 T US$
14,7 T US$
-20,5 T US$
-3,5 T US$
25,4 T US$
25,3 T US$
29,1 T US$
76,9 T US$
8,1%
—
6,9%
—
2025-12-31
447,6 T US$
23,1 T US$
12,1 T US$
19,7 T US$
16,1 T US$
3,6 T US$
4,4 T US$
971 Tr US$
5,5 T US$
7,9 T US$
726 Tr US$
-8,7 T US$
-11,6 T US$
25,3 T US$
24,4 T US$
28,1 T US$
78,4 T US$
4,2%
—
5,2%
—
§9 So sánh định giá với các doanh nghiệp cùng ngành
Giá trị hợp lýReport-date price
UnitedHealth Group IncorporatedUNH
Giá / giá trị hợp lý
Giá trị hợp lý448,25 US$Report-date price376,9 US$
Ngày đánh giá
Hào kinh tếNarrow
Bảng điểm đầu tư63 / 100
CVS Health CorporationCVS
Giá / giá trị hợp lý
Giá trị hợp lý107,29 US$Report-date price93,45 US$
Ngày đánh giá
Hào kinh tếNarrow
Bảng điểm đầu tư58 / 100
Elevance Health Inc.ELV
Giá / giá trị hợp lý
Giá trị hợp lý474,64 US$Report-date price434,13 US$
Ngày đánh giá
Hào kinh tếNarrow
Bảng điểm đầu tư61 / 100
UnitedHealth Group IncorporatedUNH
Giá / giá trị hợp lý
Giá trị hợp lý448,25 US$Report-date price376,9 US$
UnitedHealth Group Incorporated (UNH) trades at 16.7x forward earnings against a peer median of 12.2x. Its EV/EBITDA of 14.5x compares with a peer median of 10.3x. The comparison uses 4 peers: CVS Health Corporation, Elevance Health Inc., The Cigna Group and Amgen Inc., as of 2026-09-20.
§10 Ngành và chu kỳEN
Pha chu kỳ
Contraction
Industry capex-to-revenue benchmark stands at 0.90% and capex-to-depreciation at 0.81, matching UNH's capital spending of $3,622M against $4,361M depreciation in FY2025.
Chu kỳ tăng giá
Favorable demographics driving Medicare Advantage enrollment growth, expanding value-based care adoption, and commercial pricing updates compensating for medical cost trends.
Chu kỳ giảm giá
Tightening CMS statutory reimbursement rates, V28 risk adjustment model coding phase-ins, elevated outpatient utilization, and heightened antitrust scrutiny on PBM practices.
Xu hướng dài hạn
Xu hướng
Tác động
Ghi chú
Aging US Population and Medicare Advantage Expansion
positive
Long-term demographic growth expands the addressable market for senior care delivery and health benefit plans.
Stricter CMS Risk Adjustment and Reimbursement Scrutiny
negative
Federal rate benchmarks and risk coding adjustments reduce baseline payment growth per Medicare Advantage enrollee.
Payer-Provider Vertical Integration
positive
Coordinating care delivery, pharmacy services, and benefit management lowers total medical costs relative to fragmented peers.
Định vị
As the largest managed care organization in the United States, UNH is positioned to capture value-based care volumes while absorbing regulatory margin friction better than smaller peers.
§11 Quản lý vị thếEN
Quy mô vị thế
4-6%
Reflects the company's defensive mature compounder profile, strong cash generation, and attractive discount to Fair value of $448.25 relative to the report-date price of $376.90, balanced against CMS regulatory concentration risks.4
Rủi ro
Maintain strict position size discipline capped at 6% of equity portfolio. Rebalance exposure if Medicare Advantage regulatory rate decisions or unexpected medical loss ratio spikes impair forward cash flow generation.
Đợt vào lệnh
Mức
Hành động
Lý do
Below $380.00
Initiate primary tranche (50% of target allocation)
Trades at an attractive discount to Fair value ($448.25) with forward P/E of 16.72x.
Pause new capital additions and conduct a full re-underwrite of long-term margin recovery assumptions.
optumhealth_operating_income
Operating loss at or below -$500M
Demote valuation model multiples and reduce target position sizing by 25%.
§12 Quan điểm nhà đầu tưEN
Value Investor
Buy
Trading at 16.72x forward earnings and a 15.92% discount to our Fair value of USD 448.25, UNH offers an attractive entry into a premier healthcare compounder with strong 1.63x cash conversion.4,6
Growth Investor
Buy
While near-term revenue growth is modest, Optum's clinical expansion and integrated pharmacy services underpin consensus EPS expectations of $22.61 in FY2027, supporting a near-term earnings rebound and long-term recovery as margins normalize.2
Income & Quality Investor
Buy
Disciplined capital allocation returning $7.9B in dividends and $5.5B in repurchases in FY2025, combined with robust free cash flow of $16.1B, offers dependable income and consistent per-share compounding.5
§14 Khuyến nghị cuối cùngEN
Hành động
Mua
We recommend a Buy rating on UnitedHealth Group. At the report-date price of USD 376.90, shares trade at a 15.92% discount to our Fair value of USD 448.25, presenting an attractive risk-reward profile for long-term investors.4
The company's core scale across UnitedHealthcare ($344.9B revenue) and OptumRx ($7.19B operating profit) provides defensive cash flow and pricing power. Robust free cash flow of $16.1B supports steady dividend growth and share repurchases.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
OptumHealth generated an operating loss of -$278M in FY2025 on $101,957M revenue. If capitation deficits escalate past -$1,000M, the house forecast margin recovery fails completely.7
FV impact
-1.5%
The analyst's bear scenario path and multiple as the base case
UNH trades at 16.72x forward P/E with an 18.0x modeled terminal P/E, while peers trade at CVS 10.42x, ELV 13.91x, and CI 8.23x. A 20% multiple compression to 14.4x aligns UNH with peer levels.3,4
FV impact
-1.9%
Terminal multiple 20% lower
Trigger
Within 24 months
Widening capitation deficits in care delivery clinics failing to absorb provider wage and clinical inflation on $102.0B revenue.
Hiện tại:-$278M in FY2025
Cảnh báo nếuat or below -$500M
03
unitedhealthcare_operating_margin
Commercial and Medicare Advantage underwriting margins compressing under elevated medical care ratios, impairing core cash flow.
Limitation: Terminal value is 65% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
03
Chỉ số:
OptumHealth Clinical Care Profitability
Hiện tạiOperating at a deficit in the baseline fiscal year under capitation contract pressures.
Vì sao quan trọng
Return to positive operating profit is required to reach the long-term consolidated margin target.
04
Chỉ số:
OptumRx Pharmacy Services Margin Stability
Hiện tạiConsistently profitable and generating reliable operational cash flow.
Vì sao quan trọng
Sustains steady fee income and purchasing scale to buffer clinical underwriting volatility.
